Trials / Completed
CompletedNCT02324140
Inflammatory Response in Aortic Valve Replacement
The Impact of Genetic Variability on Perioperative Morbidity and Mortality. Substudy: Inflammatory Response in Patients Undergoing Aortic Valve Replacement.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 101 (actual)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates inflammatory and antiinflammatory response in patients with severe aortic valve stenosis needing either surgical treatment (surgical aortic valve replacement) or interventional cardiology treatment (transcatheter aortic valve implantation using the transfemoral access route or the transapical access route).
Detailed description
Background Surgical and interventional therapy for aortic valve stenosis exposes the patients to a immune reaction, which is different depending on the type of the treatment. In this study, the investigators would like to better understand the inflammatory and antiinflammatory response in this patient population by monitoring the perioperative cytokine response (interleukins), the human leukocyte antigen expression (HLA-DR) and assessing soluble plasma factors (CD62L) involved in inflammatory processes. Objective Characterisation of inflammatory and antiinflammatory response in patients receiving aortic valve prosthesis selected for different treatment options. Methods Whole blood analysis at different time points (preoperatively, 4 / 24 /48 hours postoperatively) for different inflammatory and antiinflammatory markers: IL-6, IL-8, IL-10, CRP, TNF, soluble CD62L.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Whole blood analysis | In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-03-01
- Completion
- 2015-05-01
- First posted
- 2014-12-24
- Last updated
- 2015-07-14
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02324140. Inclusion in this directory is not an endorsement.